Advertisement

Topics

Galapagos announces phase IIa results with GLPG1690 in IPF patients

09:03 EDT 11 Aug 2017 | CentreWatch

Galapagos NV has announced positive topline results with its autotaxin inhibitor GLPG1690 in patients with idiopathic pulmonary fibrosis (IPF) in the FLORA phase IIa trial. FLORA was an exploratory, randomized, double-blind, placebo-controlled trial investigating a once-daily oral dose of GLPG1690. The drug candidate was administered for 12 weeks in 23 IPF patients, 17 of whom received […]

The post Galapagos announces phase IIa results with GLPG1690 in IPF patients appeared first on CenterWatch News Online.

Original Article: Galapagos announces phase IIa results with GLPG1690 in IPF patients

NEXT ARTICLE

More From BioPortfolio on "Galapagos announces phase IIa results with GLPG1690 in IPF patients"

Quick Search
Advertisement
 

Relevant Topics

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...